Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMREC: Neoadjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
NCT04109755Phase 2Recruiting
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in rectal cancer. Primary endpoint: Tumour Regression Grade at 12 weeks. Started Jun 2020; status: recruiting.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04109755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109755.